T. Rowe Price Investment Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $179M | Sell |
3,683,026
-115,077
| -3% | -$5.6M | 0.11% | 191 |
|
|
2025
Q1 | $129M | Sell |
3,798,103
-13,605
| -0.4% | -$463K | 0.09% | 231 |
|
|
2024
Q4 | $150M | Buy |
3,811,708
+1,074,238
| +39% | +$42.3M | 0.09% | 223 |
|
|
2024
Q3 | $129M | Buy |
2,737,470
+6,818
| +0.2% | +$320K | 0.08% | 248 |
|
|
2024
Q2 | $147M | Buy |
2,730,652
+26,321
| +1% | +$1.42M | 0.09% | 218 |
|
|
2024
Q1 | $184M | Sell |
2,704,331
-906,855
| -25% | -$61.8M | 0.11% | 204 |
|
|
2023
Q4 | $226M | Sell |
3,611,186
-40,647
| -1% | -$2.54M | 0.15% | 164 |
|
|
2023
Q3 | $166M | Buy |
3,651,833
+5,251
| +0.1% | +$238K | 0.12% | 201 |
|
|
2023
Q2 | $205M | Sell |
3,646,582
-17,789
| -0.5% | -$999K | 0.14% | 166 |
|
|
2023
Q1 | $166M | Buy |
3,664,371
+670,794
| +22% | +$30.3M | 0.12% | 181 |
|
|
2022
Q4 | $122M | Buy |
2,993,577
+752,132
| +34% | +$30.6M | 0.09% | 221 |
|
|
2022
Q3 | $146M | Buy |
+2,241,445
| New | +$146M | 0.12% | 181 |
|